NCT00000199 is a Phase 1 clinical trial of Piracetam in Cocaine-Related Disorders, sponsored by University of Pennsylvania.

Who is sponsoring NCT00000199?

NCT00000199 is sponsored by University of Pennsylvania.

What drugs are being tested in NCT00000199?

Interventions in NCT00000199: Piracetam.

What condition does NCT00000199 study?

NCT00000199 studies Cocaine-Related Disorders.

Is NCT00000199 still recruiting?

NCT00000199 is currently withdrawn. Last updated 30 March 2017.

Last reviewed 2017-03-30 · How we verify

NCT00000199

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Piracetam for Treatment of Cocaine Addiction, Phase II - 4

Withdrawn Phase 1 Last updated 30 March 2017

What this trial tests

Phase 1 trial testing Piracetam in Cocaine-Related Disorders. Withdrawn.

Quick facts

Lead sponsor	University of Pennsylvania
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Primary purpose	treatment
Sites	1 location across United States

Drugs / interventions tested

Piracetam — full drug profile →

Conditions studied

Cocaine-Related Disorders — all drugs for Cocaine-Related Disorders →

Sponsor

University of Pennsylvania

Who can join

Eligibility, any sex, with Cocaine-Related Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to follow patients in Phase I of an inpatient study in an eight week open label assessment of piracetam in an outpatient treatment program.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Piracetam

Trials testing the same drug.

NCT06479629 — The Effect of Piracetam on Diabetic Peripheral Neuropathy Patients · Phase 4 · not yet recruiting
NCT05918341 — Subtherapeutic Dose of Piracetam as a Therapy Adherence Marker · Phase 4 · unknown

Other University of Pennsylvania trials

Trials by the same sponsor.

NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00000199 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
Last refreshed: 30 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00000199.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing